Sep 21, 2025, 07:47
WFH: Hemophilia Innovations from Factor Therapy to Gene Therapy
World Federation of Hemophilia (WFH) shared on X:
”Hemophilia has led rare disease innovation—from factor therapy to Gene Therapy—thanks to decades of advocacy and investment. But continued progress depends on sustained support. The future of treatment access is in our hands.
Read more in Blood Advances:”
Find similar posts on Hemostasis Today.
-
Aug 25, 2026, 00:07Muhammad Ali Khan: Using EHR Data to Predict Fibrotic Progression in PV and ET
-
Aug 25, 2026, 00:06Michael R. Scoma: The Vascular Dimension of Long COVID
-
Aug 24, 2026, 23:40Vimee Bindra: Your Period May Be Trying to Tell You Something
-
Aug 24, 2026, 23:30R. P. Singh: Hemophilia and HIV Relationship
-
Aug 24, 2026, 23:12Marta Velia Antonini: Hemolysis in ECMO – More Than Just a Laboratory Finding
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada